Tempus receives FDA approval for tumor-only xT CDx genomic test

May 29, 2026 8:15 AM

Tempus AI Inc. (NASDAQ: TEM) announced the U.S. Food and Drug Administration has approved a tumor-only indication for its xT ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found